Pfizer (NYSE:PFE) Shares Acquired Rep. Laurel M. Lee

Representative Laurel M. Lee (R-Florida) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $15,001 and $50,000 in Pfizer stock on October 21st.

Representative Laurel M. Lee also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of GE Vernova (NYSE:GEV) on 11/8/2024.
• Purchased $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 10/7/2024.
• Purchased $50,001 – $100,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 9/10/2024.

Pfizer Stock Performance

PFE stock traded up $0.52 during midday trading on Friday, reaching $25.65. The company had a trading volume of 41,896,988 shares, compared to its average volume of 54,672,200. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $28.21 and a 200 day moving average price of $28.57. The firm has a market capitalization of $145.36 billion, a PE ratio of 34.66, a P/E/G ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the business posted ($0.17) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Pfizer

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. acquired a new position in Pfizer during the first quarter valued at $315,000. Edgestream Partners L.P. purchased a new stake in Pfizer in the 1st quarter worth approximately $243,000. EP Wealth Advisors LLC boosted its stake in shares of Pfizer by 0.9% during the 1st quarter. EP Wealth Advisors LLC now owns 336,062 shares of the biopharmaceutical company’s stock valued at $9,326,000 after buying an additional 2,864 shares during the period. Stonebridge Capital Advisors LLC increased its stake in shares of Pfizer by 35.2% in the first quarter. Stonebridge Capital Advisors LLC now owns 26,586 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 6,921 shares during the last quarter. Finally, Gamco Investors INC. ET AL raised its holdings in shares of Pfizer by 123.9% during the first quarter. Gamco Investors INC. ET AL now owns 533,251 shares of the biopharmaceutical company’s stock worth $14,798,000 after acquiring an additional 295,139 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of several analyst reports. Barclays raised their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

About Representative Lee

Laurel Lee (Republican Party) is a member of the U.S. House, representing Florida’s 15th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2025. Lee (Republican Party) is running for re-election to the U.S. House to represent Florida’s 15th Congressional District. She declared candidacy for the Republican primary scheduled on August 20, 2024. Gov. Ron DeSantis (R) appointed Lee to serve as the Florida Secretary of State on January 28, 2019, after the resignation of Michael Ertel on January 24. Lee resigned on May 16, 2022. Lee was a judge of the 13th Judicial Circuit Court in Florida from 2013 to 2019. She was appointed to the court by Gov. Rick Scott (R) in May 2013. She was elected to the position in 2014. Laurel Lee earned undergraduate and law degrees from the University of Florida. Lee’s career experience includes working as an attorney with Carlton Fields, P.A., an assistant federal public defender and assistant U.S. attorney with the United States District Court for the Middle District of Florida, and a law clerk to James S. Moody on the United States District Court for the Middle District of Florida.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.